{"id":"W3105812043","doi":"10.1016/s0140-6736(20)32292-3","title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":324,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Institute of Cancer Research; University of Calgary","funders":"Cancer Research UK","keywords":"Bortezomib; Dexamethasone; Medicine; Multiple myeloma; Proteasome inhibitor; Clinical endpoint; Internal medicine; Population; Clinical trial; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009687358,0.0005814129,0.001760412,0.0001425563,0.0002635317,0.0002176424,0.0005331523,0.0001811769,0.0001587707],"category_scores_gemma":[0.001908014,0.0003742995,0.00007289052,0.0005000588,0.0004214538,0.0003634456,0.0003708072,0.0007768993,0.00004838015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001373356,"about_ca_system_score_gemma":0.0002828969,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000695655,"about_ca_topic_score_gemma":0.000351072,"domain_scores_codex":[0.9959959,0.0005423031,0.0006800374,0.0009739275,0.0008000786,0.001007754],"domain_scores_gemma":[0.9963743,0.001536528,0.0002638387,0.0008249179,0.000192133,0.0008082655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8937979,0.003851945,0.05190236,0.0001354842,0.0007155323,0.0002179694,0.001356555,0.000002767018,0.00102411,0.00001576857,0.001606573,0.045373],"study_design_scores_gemma":[0.9239312,0.01826327,0.04926987,0.0001610652,0.000398572,0.00001799114,0.0003317055,0.002342781,0.0004937472,0.00001537849,0.004333532,0.0004408313],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866751,0.001208753,0.00008851947,0.004443195,0.0001442797,0.006359615,0.000302718,0.00009736353,0.000680409],"genre_scores_gemma":[0.9899471,0.0005533457,0.006657115,0.001236044,0.0006296766,0.0004732242,0.0002996672,0.00009423729,0.0001096348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04493217,"threshold_uncertainty_score":0.9998709,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1084690263159896,"score_gpt":0.353852140548447,"score_spread":0.2453831142324574,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}